Allan Perley Jarvis

Prokarium Ltd. operates as a biopharmaceutical company that focuses on developing vaccination solutions based on synthetic biology. Its oral vaccine delivery platform Vaxonella stimulates broad protective immune responses applicable to a wide range of diseases. The company is headquartered in Keele, the United Kingdom.

Prokarium Holdings Ltd. provides management services. The private company is based in London, UK. The British company was founded in 2014. Kristen Albright has been the CEO of the company since 2018.